TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21831359
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER Low (1.5 mg)
Study: 21831359
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER High (6 mg)
Study: 21831359
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER (3 mg)
Study: 21831359
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER (12 mg)
Study: 17676687
Drug: 10 weekly
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 weekly group CBT sessions
Study: 28991664
Drug: Standard rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rehabilitation treatment (control group)
Study: 21869712
Drug: Triamcinolone hexacetonide
Normalized name: Triamcinolone Hexacetonide
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone hexacetonide (TAH) 20 mg
Study: 18543492
Drug: Chemotherapy (NP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (NP or GP protocol)
Study: 18543492
Drug: YYJD and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: YYJD and chemotherapy in combination
Study: 14692211
Drug: Colgate Cavity
Normalized name: DELTA COMFORT PLUS 2019 AMENITY With Colgate Cavity Protection KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colgate Cavity Protection Winterfresh Gel (0.243% sodium fluoride)
Study: 8465010
Drug: Pre‐ or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐ or postoperative megavoltage radiation therapy (45 Gy/5 weeks)
Study: 8465010
Drug: Pre‐ or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐ or postoperative megavoltage radiation therapy
Study: 25227114
Drug: Early goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early goal-directed therapy using arterial waveform analysis
Study: 20144066
Drug: Benidipine (4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine (4-8 mg/day) combined with olmesartan (10 mg/day)
Study: 20144066
Drug: Amlodipine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5-10 mg/day) combined with olmesartan (10 mg/day)
Study: 11213073
Drug: 2 mg/day
Normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/day sirolimus
Study: 11213073
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day sirolimus
Study: 9627862
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 mg 3 times a day for 1 week, 800 mg twice a day for 1 week, and 800 mg as needed to a maximum daily dose of 2400 mg for 7 weeks) and nocturnal wrist supports
Study: 9627862
Drug: Chiropractic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic treatment (manipulation of soft tissues and bony joints of the upper extremities and spine, ultrasound over the carpal tunnel, and nocturnal wrist supports)
Study: 7877194
Drug: Captopril (37.5-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (37.5-75 mg/d)
Study: 7877194
Drug: Nadolol (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (40-80 mg/d)
Study: 3048092
Drug: Cefixime (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (400 mg once daily)
Study: 3048092
Drug: Amoxicillin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (250 or 500 mg three times daily)
Study: 28080323
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of ATP as disodium salt
Study: 17163255
Drug: Paracetamol 1g
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol 1g plus ciprofloxacin 500mg
Study: 9322521
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg daily for 4 weeks)
Study: 4056256
Drug: Nifedipine aerosol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine aerosol, 10 mg in 40% ethanol
Study: 22747856
Drug: Drug lymphocyte
Normalized name: lymphocyte immune globulin, anti-thymocyte globulin Injection [ATGAM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug lymphocyte stimulation test (DLST) performed at Week 1 of adverse reactions
Study: 22747856
Drug: Drug lymphocyte
Normalized name: lymphocyte immune globulin, anti-thymocyte globulin Injection [ATGAM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug lymphocyte stimulation test (DLST) performed 2 months after the reaction (Group A)
Study: 22747856
Drug: Drug lymphocyte
Normalized name: lymphocyte immune globulin, anti-thymocyte globulin Injection [ATGAM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug lymphocyte stimulation test (DLST) performed >12 months after the reaction (Group B)
Study: 18768511
Drug: MTHFR 1298
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTHFR 1298 CC genotype
Study: 12456031
Drug: 6% hydroxy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydroxy ethyl starch solution (10 ml/kg, 30 minutes)
Study: 12456031
Drug: FPSA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPSA treatment
Study: 8534744
Drug: Dialysis solution
Normalized name: dialysis solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis solution at a sodium concentration of 126 mEq/L (low sodium)
Study: 8534744
Drug: Dialysis solution
Normalized name: dialysis solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis solution at a sodium concentration of 132 mEq/L (normal sodium)
Study: 2014078
Drug: Amnioinfusion with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amnioinfusion with warmed saline solution
Study: 6517242
Drug: Amezinium methylsulfate
Normalized name: amezinium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amezinium methylsulfate 5 mg i.v. given if blood pressure dropped greater than 20 mmHg
Study: 24238984
Drug: No helmet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No helmet therapy (control)
Study: 22441566
Drug: Cetuximab-based treatment
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab-based treatment
Study: 22441566
Drug: Bevacizumab-based treatment
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab-based treatment
Study: 20008831
Drug: Mipomersen 200
Normalized name: mipomersen 200 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 200 mg weekly for 13 weeks
Study: 17413113
Drug: Vegetable group
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable group (5.6 mg beta-carotene/d from green leafy vegetables)
Study: 17413113
Drug: Fruit group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit group (4.8 mg beta-carotene/d from orange or yellow fruit)
Study: 17413113
Drug: Retinol-rich group
Normalized name: retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Retinol-rich group (610 microg retinol/d from animal foods and 0.6 mg beta-carotene/d)
Study: 17413113
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.4 mg beta-carotene/d)
Study: 11115437
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone 10 mg qd
Study: 9363727
Drug: Pentoxifylline (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (800 mg/day for 12 months)
Study: 1543782
Drug: Peritoneal dialysis
Normalized name: Peritoneal dialysis solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal dialysis fluid (2.0 L)
Study: 28660740
Drug: PEG-asparaginase (Oncaspar®)
Normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-asparaginase (Oncaspar®) 1,000 IU/m²/dose, administered biweekly
Study: 21171937
Drug: Testosterone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (250 mg of testosterone enanthate every 4 weeks)
Study: 18053317
Drug: Simvastatin (10-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10-80 mg)
Study: 14640465
Drug: Atorvastatin (10-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10-80 mg)
Study: 18053317
Drug: Ezetimibe and
Normalized name: Ezetimibe and Simvastatin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe and statins (co-administration)
Study: 12625376
Drug: DDAT exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAT exercise programme used daily at home
Study: 12625376
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (same treatment at school, no DDAT exercise programme)
Study: 1528786
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate (CH) 25 mg/kg
Study: 1528786
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate (CH) 70 mg/kg
Study: 22545212
Drug: Electrical muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical muscle stimulation (EMS) applied daily on vastus lateralis, vastus medialis, and peroneus longus of both lower extremities.
Study: 21125816
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg entecavir dispersible tablets under fasted conditions
Study: 21125816
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg entecavir dispersible tablets under fed conditions
Study: 15502051
Drug: Oxymorphone IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone IR 10 mg
Study: 15502051
Drug: Oxymorphone IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone IR 20 mg
Study: 17692717
Drug: Oxycodone IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone IR 15 mg
Study: 15119915
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg q.d.
Study: 9444883
Drug: Preliminary data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preliminary data showing 9 out of 10 patients improved with drug A
Study: 9444883
Drug: Preliminary data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preliminary data showing 5 out of 10 patients improved with drug B
Study: 16366815
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (0 mg)
Study: 3174738
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (8 mg)
Study: 27163830
Drug: Transdermal 17β-estradiol
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17β-estradiol (50μg/day)
Study: 27163830
Drug: Oral CEE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CEE (0.45 mg/day)
Study: 25183926
Drug: Levobupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine with 1ml of isotonic saline (Group L)
Study: 17647003
Drug: CCR5 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCR5 inhibitor SCH351125
Study: 10480473
Drug: Irbesartan monotherapy
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan monotherapy (0, 37.5, 100, and 300 mg)
Study: 10480473
Drug: HCTZ monotherapy
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCTZ monotherapy (0, 6.25, 12.5, and 25 mg)
Study: 1747725
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose alpha-2b interferon (10 x 10(6) IU)
Study: 1747725
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose alpha-2b interferon (100 x 10(6) IU)
Study: 27307305
Drug: broad-spectrum antibiotics
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: broad-spectrum antibiotics (ciprofloxacin, vancomycin and metronidazole) for 7 days
Study: 27307305
Drug: broad-spectrum antibiotics
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: broad-spectrum antibiotics
Study: 26308780
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health intervention for medication adherence and blood pressure control (3-month duration)
Study: 24436453
Drug: Vaginally applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginally applied tenofovir gel
Study: 19023644
Drug: Methylprednisolone (MTP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MTP) 40 mg
Study: 19023644
Drug: Triamcinolone (TMC)
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone (TMC) 40 mg
Study: 15138948
Drug: Intervention hospitals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention hospitals with sequential directed education and personalized feedback strategies
Study: 10867040
Drug: 5.0 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 g/d HPMC in 240 mL of orange drink taken between meals
Study: 10867040
Drug: 5.0 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 g/d HPMC in 240 mL of orange drink taken with meals
Study: 2859136
Drug: Triazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.25 mg) + Ethanol (800 to 950 mg/L)
Study: 3070032
Drug: Verapamil (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (doses of 40 to 120 mg, twice daily for six weeks)
Study: 28243132
Drug: SQ HDM
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ HDM SLIT-tablet in addition to allergy pharmacotherapy
Study: 28243132
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus allergy pharmacotherapy
Study: 28822510
Drug: 80-mg atorvastatin
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-mg atorvastatin
Study: 28822510
Drug: 10-mg atorvastatin
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg atorvastatin
Study: 16715326
Drug: Constant flow
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant flow insufflation of oxygen (CFIO) at a flow rate of 15 l/min
Study: 8238158
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral tocolytic (Control)
Study: 2930998
Drug: Zimeldine, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimeldine, 100 mg b.i.d.
Study: 2930998
Drug: Maprotiline, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline, 75 mg b.i.d.
Study: 27497358
Drug: Metal drug-eluting
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metal drug-eluting stent (DES)
Study: 8237933
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg bid
Study: 8237933
Drug: Clarithromycin 1000
Normalized name: clarithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 1000 mg bid
Study: 8237933
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg qid
Study: 3535491
Drug: Clotrimazole 10
Normalized name: clotrimazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 10 mg troches, three times per day
Study: 20358155
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg once daily for eight weeks
Study: 20358155
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg once daily for eight weeks
Study: 20358155
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enalapril 10 mg and losartan 50 mg daily for eight weeks
Study: 17016955
Drug: Anthelmintic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthelmintic therapy
Study: 10477530
Drug: Candesartan (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (4, 8, or 16 mg)
Study: 10477530
Drug: Candesartan (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (4 or 8 mg) plus 20 mg of enalapril
Study: 1769411
Drug: Chemoimmunotherapy (bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoimmunotherapy (bacillus Calmette‐Guérin + chemotherapy)
Study: 1769411
Drug: Immunotherapy (bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (bacillus Calmette‐Guérin alone)
Study: 1769411
Drug: Immunotherapy (specifically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (specifically for lower limb malignant melanoma)
Study: 6280621
Drug: Unrefined diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unrefined diet (whole foods, 60 g/day dietary fibre)
Study: 6280621
Drug: Refined diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined diet (processed foods, 20 g/day dietary fibre)
Study: 11586056
Drug: Glucose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (50 mg)
Study: 7768076
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of dofetilide (0.5 mg over 30 minutes)
Study: 7768076
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of dofetilide (0.5 mg)
Study: 7768076
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of dofetilide (0.5 mg)
Study: 496237
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine mixed with dextran 40 solution
Study: 31841570
Drug: Weekly religious
Normalized name: red delicious apple allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly religious activities
Study: 28299455
Drug: Palmitoylethanolamide (PEA)
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitoylethanolamide (PEA) 300 mg twice a day for 60 days
Study: 26428224
Drug: Gastrografin in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrografin in addition to conservative treatment
Study: 22169269
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (74 Gy in 37 fractions of 2 Gy)
Study: 22169269
Drug: Hypofractionated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated treatment (60 Gy in 20 fractions of 3 Gy)
Study: 22169269
Drug: Hypofractionated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated treatment (57 Gy in 19 fractions of 3 Gy)
Study: 21058472
Drug: Needling therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needling therapy (local and distal points and points selection according to the differentiation)
Study: 21058472
Drug: Auricular electroacupuncture
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular electroacupuncture therapy
Study: 17047932
Drug: MDMA 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA 1.5 mg/kg with Fluoxetine 20 mg
Study: 16143048
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg orally
Study: 16143048
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg rectally
Study: 16143048
Drug: 35 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg/kg rectally
Study: 16143048
Drug: Rectal high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal high-dose (35 mg/kg)
Study: 12490213
Drug: Rhizophora mangle
Normalized name: CATH,THORACIC RT ANGLE 28FR K#573048
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhizophora mangle aqueous bark extract (twice a day)
Study: 12490213
Drug: mercurocrome (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: mercurocrome (twice a day)
Study: 9009112
Drug: Cholecystokinin octapeptide
Normalized name: Cholecystokinin C-terminal octapeptide
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cholecystokinin octapeptide (CCK-OP) 30 ng/kg stat and 60 ng/kg/hr by infusion
Study: 9009112
Drug: Atropine 0.01
Normalized name: atropine 0.0194 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.01 mg/kg stat and 0.01 mg/kg/hr by infusion
Study: 3107289
Drug: Thyrotropic releasing
Normalized name: Thyrotropic releasing hormone
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thyrotropic releasing hormone (TRH)
Study: 26879827
Drug: Pitolisant 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitolisant 200 mg
Study: 26879827
Drug: Pitolisant 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitolisant 240 mg
Study: 26879827
Drug: Pitolisant 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitolisant 120 mg
Study: 26879827
Drug: SAD study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SAD study at 240 mg
Study: 26879827
Drug: TQT study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TQT study at 120 mg
Study: 12384852
Drug: Atovaquone/proguanil (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone/proguanil (4 tablets per day for 3 days)
Study: 1840344
Drug: Midazolam (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.07 mg/kg i.v.)
Study: 1840344
Drug: Diazepam (0.14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.14 mg/kg i.v.)
Study: 1840344
Drug: Placebo (saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline, 0.07 ml/kg i.v.)
Study: 7049312
Drug: surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: surgery plus 2000 rad (20 Gy) in 10 equal daily fractions
Study: 28536741
Drug: Community-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based intervention targeted at treatment adherence
Study: 22546741
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence assessment using the Morisky Medication Adherence Scale